Additionally, CAPE is effective in combating MDR in lung and prostate cancer by downregulating the synthesis of claudin-2, suppressing the NF-κB pathway, diminishing cytoplasmic reserves of GSH (reduced glutathione), and decreasing apoptotic regulators (cIAP1, cIAP-2, and XIAP) [362,363]. Here, CLDN2 is linked to prostate carcinoma.